![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/c/cd/Necitumumab_EGFR_6B3S.png/640px-Necitumumab_EGFR_6B3S.png&w=640&q=50)
Necitumumab
Recombinant human monoclonal antibody / From Wikipedia, the free encyclopedia
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[3] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[4][5][6] It was counterproductive in non-squamous non-small-cell lung carcinoma.[6][7]
Quick Facts Monoclonal antibody, Type ...
![]() | |
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | EGFR |
Clinical data | |
Trade names | Portrazza |
AHFS/Drugs.com | Multum Consumer Information |
License data |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | ~14 days |
Identifiers | |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
Chemical and physical data | |
Formula | C6436H9958N1702O2020S42 |
Molar mass | 144844.87 g·mol−1 |
![]() ![]() |
Close